Pharmasum Therapeutics: Difference between revisions
Created from NHT member research |
Created with researched data |
||
| Line 1: | Line 1: | ||
{{ | {{DISPLAYTITLE:Pharmasum Therapeutics}} | ||
|name=Pharmasum Therapeutics | {{Infobox company | ||
| | | name = Pharmasum Therapeutics AS | ||
| | | org_number = 913746430 | ||
| | | founded = 2014-06-02 | ||
|funding= | | employees = Not disclosed | ||
| | | address = Norway | ||
| industry = 72.100 – Biotechnology research | |||
| website = https://www.pharmasum.com | |||
| nht_category = Startup | |||
| description = Pharmasum Therapeutics is developing drugs for dementia. Dementia is a group of neurodegenerative diseases causing gradual loss of brain function — memory, cognition, daily activities. Pharmasum is addressing one of the largest unmet healthcare challenges of today. | |||
| notes = No disclosed revenue, funding, or employees. Founded 2014. Dementia drug development is extremely high-risk/high-reward. | |||
| related_companies = [[Hemispherian]], [[Exact Therapeutics]], [[Nextera]], [[Nordic Brain Tech]], [[Norway Health Tech]] | |||
| categories = Norway Health Tech, Startups, Biotechnology, Drug Development, Neurology | |||
| sources = https://www.pharmasum.com; https://data.brreg.no/enhetsregisteret/api/enheter/913746430 | |||
}} | }} | ||
== | == About == | ||
Pharmasum Therapeutics AS is a Norwegian biotechnology company developing drugs for the treatment of dementia. Founded in 2014. | |||
== | == Focus Area == | ||
Dementia is characterized by a group of neurodegenerative diseases leading to gradual loss of brain function, including: | |||
* | * Memory loss | ||
* | * Cognitive decline | ||
* | * Loss of daily living activities | ||
[[Category: | Pharmasum describes dementia as one of the largest unmet healthcare challenges of today. | ||
[[Category: | |||
== Market == | |||
Dementia affects approximately 55 million people globally, with the World Health Organization projecting this number to triple by 2050. Alzheimer's disease is the most common form. The field has seen significant recent investment and regulatory activity (Lecanemab, Donanemab approvals), but substantial unmet need remains. | |||
== Research Status == | |||
At the time of this research, limited public information was available about Pharmasum's specific technology or pipeline stage. | |||
== References == | |||
<references/> | |||
[[Category:Norway Health Tech]] | |||
[[Category:Startups]] | |||
[[Category:Biotechnology]] | |||
[[Category:Drug Development]] | |||
[[Category:Neurology]] | |||
Latest revision as of 20:32, 14 April 2026
About[edit]
Pharmasum Therapeutics AS is a Norwegian biotechnology company developing drugs for the treatment of dementia. Founded in 2014.
Focus Area[edit]
Dementia is characterized by a group of neurodegenerative diseases leading to gradual loss of brain function, including:
- Memory loss
- Cognitive decline
- Loss of daily living activities
Pharmasum describes dementia as one of the largest unmet healthcare challenges of today.
Market[edit]
Dementia affects approximately 55 million people globally, with the World Health Organization projecting this number to triple by 2050. Alzheimer's disease is the most common form. The field has seen significant recent investment and regulatory activity (Lecanemab, Donanemab approvals), but substantial unmet need remains.
Research Status[edit]
At the time of this research, limited public information was available about Pharmasum's specific technology or pipeline stage.